Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Otis Worldwide Corp (OTIS) Price & Performance

Medpace Holdings IncTrade
Otis Worldwide CorpTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Otis Worldwide Corp — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Otis Worldwide Corp trades at $73.45 (market cap $27.80B). The key difference: Otis Worldwide Corp is the larger of the two by market cap, and Otis Worldwide Corp pays a 2.41% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

MEDPOTIS
Market Cap
$16.90B$27.80B
Sector
TechnologyIndustrials
52-Week High
$620.59$93.62
52-Week Low
$393.42$69.34
Enterprise Value
$16.52B$35.84B
Dividend Yield
2.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Otis Worldwide Corp

Otis Worldwide (OTIS) trades at $73.82, up 1.3% for the day, with a neutral technical signal. Recent Q2 2026 earnings showed a beat on EPS but included guidance cuts, reflecting margin pressures from labor costs. The company maintains strong service segment growth, with modernization revenue up 24%, though new equipment demand remains weak. Cash flow trends show variability, with 2025 net cash flow negative $1.22 billion due to financing activities, while 2026 projects a positive $146 million.

The investment outlook is mixed; analyst consensus is a Buy with a $92.50 price target, implying significant upside, but risks include persistent margin compression and economic sensitivity. The stock's current valuation below historical averages presents a potential opportunity if service margins stabilize and growth accelerates.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Otis Worldwide Corp

Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.

Read more on OTIS